Related Experiment Video
Updated: Aug 5, 2026

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
Published on: September 14, 2013
Reducing delays in the diagnosis and treatment of Clostridium difficile diarrhoea
1Department of Gastroenterology, Wycombe Hospital, High Wycombe, UK. mfrenz@doctors.org.uk
Background:
The diagnosis of Clostridium difficile diarrhoea is often delayed.
Aim:
To assess and reduce delays in diagnosis and treatment.
Design:
Two-part study: retrospective audit then prospective observational.
Methods:
The retrospective study audited cases positive for C. difficile culture or toxin A between June 2000 and January 2001. Cases were reviewed regarding demographic characteristics and the timing from onset of symptoms to testing and treatment (n = 27). In the prospective study, efforts were made to increase the awareness of medical staff about C. difficile diarrhoea, and testing for C. difficile toxin A assay was substituted for stool culture and external toxin analysis. Data were prospectively analysed for demographic characteristics and time from onset of symptoms to testing and treatment (n = 24).
Results:
There were no significant differences in age (76 vs. 78 years), male to female ratio (1:2 vs. 1:4), reason for admission, specialty responsible, or mortality rate (40% vs. 37%) during the presenting admission. Preceding antibiotic use, the combination of antibiotics used and subsequent treatment also did not differ between groups. The time from onset of diarrhoea to sampling was reduced from 4.7 days (range 3-30) to 0.8 days (range 0-5; p = 0.05). The time from sampling to treatment was reduced from 7.7 days (5-34) to 2.8 days (2-9; p = 0.05).
Discussion:
The combination of increased awareness of C. difficile diarrhoea and the change to in-house toxin testing significantly reduced the time from onset of symptoms to sampling and treatment.
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Automated Microbial Diagnostics

